Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Trial Profile

Phase IIb Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Clinical Trial for the Assessment of Coronary Plaque Changes With RVX000222 as Determined by Intravascular Ultrasound

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Atherosclerosis; Coronary artery disease; Low HDL cholesterol
  • Focus Therapeutic Use
  • Acronyms ASSURE; ASSURE-1
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 17 Jul 2018 According to a Resverlogix Corporation media release, results fromt his trial will be preasented at Clinical Trials in Alzheimers Disease (CTAD) Asia and Alzheimers Association International Conference (AAIC)
    • 04 Apr 2018 Results (n=48) of post hoc analysis from SUSTAIN and ASSURE trials assessing the effects of pharmacologic epigenetic modulation on levels of ALP and kidney function via apabetalone published in the Kidney and Blood Pressure Research.
    • 15 Nov 2017 Results of ASSERT, SUSTAIN and ASSURE trials assessing presented at the 90th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top